Neo-Concept International

NIH researchers report that a new form of tumor infiltrating lymphocyte (TIL) therapy combined with pembrolizumab achieved 23.5% objective response rate in patients with metastatic gastrointestinal cancers, compared to 7.7% with selected TILs alone.

Dr. Joseph Sparano was recognized as a 2024 Giant of Cancer Care for his work in breast cancer and HIV-associated cancer, focusing on underserved communities.

Huntsman Cancer Institute joins myeloMATCH, an NCI-sponsored program, to match AML and MDS patients with tailored clinical trials based on their genetic profiles.

Researchers have developed TRACeR, a platform enabling the design of proteins that bind to peptide-MHC-I complexes, offering a new approach to target tumor-associated antigens.

The myeloMATCH program, a collaboration of leading cancer research organizations, has begun enrolling patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) for precision medicine trials.

The National Institutes of Health (NIH) has initiated the myeloMATCH clinical trial to evaluate precision medicine approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

The NIH has initiated myeloMATCH, a precision medicine trial, to match AML and MDS patients with treatments based on their cancer's genetic profile.

Flatiron Health study reveals community practices face resource barriers in offering oncology clinical trials, impacting patient access and representation.

Adjuvant pembrolizumab significantly extends cancer-free survival in patients with high-risk, muscle-invasive bladder cancer following surgical removal of the bladder.

A clinical trial reveals that postsurgical pembrolizumab treatment nearly doubles cancer-free survival time in high-risk, muscle-invasive bladder cancer patients compared to observation.